Lightnews — Scholar-powered news

Reposted

PLOS Biology @plosbiology.org · 2d

#Tumor-associated #astrocytes (TAAs) have unclear functions in supporting the progression of #glioblastoma. This study identifies and characterizes distinct TAA subtypes with specific adaptive responses to #TumorMicroenvironment modifications @plosbiology.org 🧪 plos.io/3WHTnFb

Distinct morphology of astrocytes in various tumor areas. Left panel: A “glial scar’” composed of reactive astrocytes surrounding the tumor core visualized by immunofluorescence (IF) staining of mouse brain sections (td tomato labelled tumor cells in red, Gfap+ astrocytes in green and DAPI stained cell nuclei in blue). Gfap+ astrocytes are barely present in the tumor core (TC) (in the magnified inset), show elongated shapes at the tumor border (BO) and star-like morphology in the surrounding brain parenchyma (BR).
Right panel: S100B+ astrocytes (in green) show different patterns, with a uniform, widespread distribution in the brain and the presence of S100B+ astrocytes in the TC and at the BO. S100B+ astrocytes in the BO are elongated, while S100B+ astrocytes farther from the TC display star-like morphology.

1 15

Reposted

Elizabeth McKenna @elizsmckenna.bsky.social · 2d

Now online in Cancer Discovery @aacrjournals.bsky.social: Screening for Tumor Microtube-Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression - by Daniel Azorín, Dirk Hoffmann, @winklerlab.bsky.social, and colleagues doi.org/10.1158/2159...

1 6 26

Reposted

EANO @eanoassociation.bsky.social · 2d

Make the most of #EANO2025 – download the official Congress App!
Access the full programme, plan your sessions, connect with fellow attendees, and stay up to date throughout the event.
🔗 Get started: www.eano.eu/eano2025/myc...
#NeuroOncology #BrainTumor #btsm #Prague2025

2 3

Reposted

EANO @eanoassociation.bsky.social · 3d

🧠 Just published in Neuro-Oncology:"Health-related quality of life and cognitive functioning in survivors of oligodendroglioma".
🔗 Read more: lnkd.in/ekTvpZtv
These topics and others will be featured at #EANO2025 in Prague – explore the full programme here: 👉 lnkd.in/eNjwGCv6

1 4

Reposted

Winkler Laboratory @winklerlab.bsky.social · 7d

How to disconnect therapy-resistant tumor networks in glioblastoma?

In our paper, online @Cancer Discovery, we built an anti-tumor microtube (TM) screening pipeline and found that Protein Kinase C activators disrupt TMs, silence Ca²⁺ “pacemakers” and boost radiotherapy.
doi.org/10.1158/2159...

1 7 29

Reposted

EANO @eanoassociation.bsky.social · 8d

#EANO2025 in Prague is just around the corner! Congrats to Darui Jin from @dkfz.bsky.social, recipient of the Best Oral Presentation Award in Translational Research. Catch the talk in OS12 on Sun, Oct 19: “AI-based histopathological classification...”👉 t1p.de/EANO2025-OS12
#NeuroOncology #AI #btsm

3 5

Reposted

EANO @eanoassociation.bsky.social · 10d

👉 We are excited to announce that the #EANO2025 Abstract Book is now available online! Download & explore it today: lnkd.in/dg79p6wM

#AbstractBook #NeuroOncology #neurosurgery #cancernurse #neuropathology #radiotherapy #AHP #btsm

4 8

Reposted

Gutmann Lab @gutmannlab.bsky.social · 11d

Excited to share our latest work in Neuro-Oncology Advances! 🥳 After comparing several potential therapies, we identified lamotrigine as a promising therapy for NF1 optic glioma, showing both tumor reduction and vision protection. Check out the work of our great team!

Head-to-head preclinical treatment design prioritizes promising therapies for neurofibromatosis type 1 optic glioma clinical translation

AbstractBackground. Authenticated preclinical brain tumor models provide unprecedented opportunities to evaluate next-generation treatments. However, some

academic.oup.com

5 13

neurooncologyhd.bsky.social @neurooncologyhd.bsky.social · 10d

As part of the call for applications below, the Heidelberg/Mannheim site is offering four clinician scientist/postdoc positions in the field of neuro-oncology in the departements of @wickwolfgang.bsky.social and @michael-platten.bsky.social. For applications use the link below.

Hertie Network (Hamburg site) @hertieneurosci.bsky.social · 17d

🚨 Call for Applications: The Hertie Network of Excellence in Clinical Neuroscience (Berlin, Bonn, Hamburg, Heidelberg/Mannheim, Munich, Tübingen) offers up to 4 postdoc/clinician scientist positions per site. Apply by Oct 31! Details 👉 www.hertie-neuroscience-hamburg.de #HertieNetwork #Jobs

Hertie Neuroscience Hamburg

www.hertie-neuroscience-hamburg.de

2 5

Reposted

Sanjeev Herr @sanjeevherr.bsky.social · 12d

I’m thrilled to report on work I led with Dr. Shawn Hervey-Jumper and Dr. Todd Hollon which shows that we can forecast where glioblastoma will recur even at time of initial resection.

It’s wonderful to see all the work I conducted during my research year @neurosurgucsf.bsky.social come together!

3 9

Reposted

Waggoner Lab @labwaggoner.bsky.social · 13d

Review @sciimmunology.bsky.social @platten-lab.bsky.social
@dkfz.bsky.social
The immunology of brain tumors
www.science.org/doi/10.1126/...

5 16

Reposted

EANO @eanoassociation.bsky.social · 15d

💡 If you have not done so yet, and would like to renew your EANO membership for 2025, please log in via EANO’s member portal to update your data and renew your membership. Please note that membership runs on the calendar year, regardless of the date of renewal.

👉 www.eano.eu/members/eano...

1 3

Reposted

Ludwig Cancer Research @ludwigcancer.bsky.social · 23d

A team led by Ludwig Lausanne’s @johannajoyce.bsky.social & former postdoc @alvarezprado.bsky.social reports a potential drug target whose loss in certain GBM cells triggers antiviral alarms to stall cell proliferation & makes GBM tumors in mice more amenable to anti-cancer immunity.
bit.ly/4nhZ7Bj

5 10

Reposted

EANO @eanoassociation.bsky.social · 22d

🧠 Recently published in Neuro-Oncology: EANS–EANO Guidelines on the Extent of Resection in Gliomas. We’re proud to share the outcome of collaborative effort by the joint task force of EANS and EANO, providing evidence-based recommendations for clinical practice.
🔗 academic.oup.com/neuro-oncolo...

10 29

Reposted

EANO @eanoassociation.bsky.social · 23d

💡Only a few seats left for the EANO Tumor Board 2025, taking place on October 15 in Prague. Join us for interactive case-based discussions and expert insights. Registration is free for EANO members. Please register by October 3.
Learn more: www.eano.eu/eanomeetings...

4 6

Reposted

EANO @eanoassociation.bsky.social · 29d

🗓 5 days left! EANO seeks an Executive Editor for Neuro-Oncology Advances, co-owned by EANO & @neuroonc.bsky.social.
🔬 Join Editor-in-Chief @wickwolfgang.bsky.social to help shape the journal’s future.
📩 For active EANO members.
Deadline: September 21, 2025
🔗 Info: www.eano.eu
#NeuroOncology #EANO

2 4

Reposted

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · 29d

🧠 EANS-EANO Guidelines on the extent of resection in gliomas.
academic.oup.com/neuro-oncolo...

@eanoassociation.bsky.social @neuroonc.bsky.social

EANS-EANO Guidelines on the extent of resection in gliomas

Abstract. Intense efforts are employed to optimize neurosurgical resection of gliomas in different clinical scenarios. However, the level of evidence emplo

academic.oup.com

1 2

Reposted

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · Sep 12

🚨 New publication in Journal of Nuclear Medicine: Retrospective Evaluation of the Correlation Between Somatostatin Receptor PET/CT and Histopathology in Patients with Suspected Intracranial Meningiomas.
jnm.snmjournals.org/content/earl...

Retrospective Evaluation of the Correlation Between Somatostatin Receptor PET/CT and Histopathology in Patients with Suspected Intracranial Meningiomas

The aim of this retrospective study was to evaluate the correlation between findings from somatostatin receptor (SSTR) PET/CT and histopathology in patients with suspected intracranial meningiomas. Me...

jnm.snmjournals.org

1 2

Reposted

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · Sep 10

Assessment of 18F-FET PET-based response in patients with gliomas using the PET RANO 1.0 criteria.
academic.oup.com/noa/advance-...

Assessment of 18F-FET PET-based response in patients with gliomas using the PET RANO 1.0 criteria

AbstractBackground. We evaluated the amino acid PET-based response assessment criteria (PET RANO 1.0) for their proficiency in predicting longer survival i

academic.oup.com

1 3

Reposted

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · Sep 10

Prognostic value of [18F]FET-PET in diffuse low-grade (grade 2) gliomas after the 2021 classification of CNS tumors.
link.springer.com/article/10.1...

Prognostic value of [18F]FET-PET in diffuse low-grade (grade 2) gliomas after the 2021 classification of CNS tumors - European Journal of Nuclear Medicine and Molecular Imaging

Purpose Amino acid PET with [18F]-fluoroethylthyrosine ([18F]FET-PET) is frequently utilized in gliomas. Most studies on prognostication based on amino acid PET comprise mixed cohorts of brain tumors ...

link.springer.com

2 4

Reposted

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · Sep 9

Tumor Versus Capillary Telangiectasia in Recurring Glioblastoma.
journals.lww.com/nuclearmed/f...
@nathaliealbert.bsky.social

Tumor Versus Capillary Telangiectasia in Recurring... : Clinical Nuclear Medicine

stant tumor manifestation. However, multimodal MRI revealed a benign capillary telangiectasia in the anterior cingulate gyrus. While 18F-FET-PET is highly sensitive for detecting tumor activity, vascu...

journals.lww.com

2 4

Reposted

Wolfgang Wick @wickwolfgang.bsky.social · Sep 8

NOA Researchers from 13 German sites led by a team from @uniheidelberg.bsky.social @Universitätsklinikum Heidelberg (UKHD) & @dkfz.bsky.social have successfully completed the multicenter study “NCT Neuro Master Match (N2M2)”.

Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial

Nature Medicine - In a phase 1/2a umbrella trial in patients with glioblastoma matching targeted therapies according to tumor molecular profiling, temsirolimus plus radiotherapy improved PFS...

rdcu.be

2 5

Reposted

Barbara Marte @barbmarte.bsky.social · Sep 6

and the News & Views www.nature.com/articles/d41...

Depriving brain tumours of an amino acid could enhance chemotherapy

Glioblastoma, an aggressive brain cancer, depends on the amino acid serine as a fuel source. A serine-deficient diet has been shown to slow tumour growth in mice.

www.nature.com

2 7

Reposted

Dan Wahl @danwahlmd.bsky.social · Sep 6

New discovery from our team defining how human brain cancers rewire the metabolism of the normal brain published this week @nature.com and led by stellar postdoc Drew Scott (comentored by @lyssiotislab.bsky.social and currently on job market with a K99/R00). www.nature.com/articles/s41...

Rewiring of cortical glucose metabolism fuels human brain cancer growth - Nature

The cortex fuels essential physiological processes with glucose-derived carbon, while gliomas fuel their aggressiveness by rerouting glucose carbon pathways and scavenging alternative carbon sources s...

www.nature.com

3 13 42

Reposted

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · Sep 5

Prediction of progression-free and overall survival following temozolomide chemoradiation using FET PET-based parameters including radiomics in patients with glioblastoma.
academic.oup.com/noa/advance-...

Prediction of progression-free and overall survival following temozolomide chemoradiation using FET PET-based parameters including radiomics in patients with glioblastoma

AbstractBackground. Early after surgery and completion of first-line radiotherapy with concomitant temozolomide, the prediction of progression-free and ove

academic.oup.com

1 5